Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma

Area of Science:

• Neuro-oncology
• Molecular biology
• Cancer therapeutics

Background:

• Tropomyosin receptor kinase B (TrkB) and epidermal growth factor receptor (EGFR) are key targets in glioblastoma (GBM).
• Functional interactions between TrkB and EGFR are known, but their combined role in GBM requires further investigation.

Purpose of the Study:

• To investigate the roles of TrkB and EGFR, and their interactions, in glioblastoma (GBM).
• To explore the potential of combined TrkB and EGFR inhibition as a therapeutic strategy for GBM.

Main Methods:

• Analysis of NTRK2 and EGFR gene expression data from The Cancer Genome Atlas (TCGA) in GBM subtypes.
• In vitro studies using A172 human GBM cells treated with TrkB and EGFR inhibitors, alone and in combination.
• In vivo studies using U87MG GBM cell xenografts in nude mice to assess tumor growth inhibition.

Main Results:

• NTRK2 expression was elevated in the proneural GBM subtype, with a significant correlation between NTRK2 and EGFR expression in G-CIMP+ samples.
• Combined TrkB and EGFR inhibition showed a more pronounced inhibitory effect on A172 GBM cells compared to single-agent treatment.
• TrkB and EGFR inhibitor combination therapy delayed tumor growth in flank xenografts at specific time points but did not significantly impact intracranial GBM growth.

Conclusions:

• Correlations between NTRK2 and EGFR expression exist in specific glioblastoma (GBM) subgroups.
• Combined inhibition of TrkB and EGFR presents a potential therapeutic strategy for GBM, particularly in cultured cells.
• Further research is warranted to optimize combination therapies targeting TrkB and EGFR in GBM.